Mass spectrometry-based metabolomics diagnostics - myth or reality?

ABSTACT Introduction:Metabolomics, one of the most high-promising technologies, is the most recently developed post-genomics discipline for developing new diagnostic tests for future implementation in medicine. More than 2,000 scientific papers, using mass spectrometry-based (MS-based) metabolomics analysis for human disease diagnostics, have been published during the past two decades, and almost every metabolomics study shows high diagnostic accuracy. However, despite the great results and promising perspectives, there are currently no diagnostic tests based on metabolomics that have been approved and introduced into clinics. Areas covered:In this report, the advantages and challenges of MS-based metabolomics are discussed with a focus on its developing role in diagnostics, and the current trends in implementing metabolomics diagnostics in the clinic. Expert opinion:In the development of new clinical diagnostics tests, MS-based metabolomics has potential as both a preliminary discovery base for routine testing and a multi-test prototype, which is hoped to be introduced into clinical practice in the near future. A laboratory-developed test (LDT) is one possible way that multi-testing could be developed.

Automated summary

This report discusses the advantages and challenges of mass spectrometry-based metabolomics in diagnostics and the current trends in implementing metabolomics diagnostics in clinics. Mass spectrometry-based metabolomics has potential as both a preliminary discovery base for routine testing and a multi-test prototype for future clinical practice, with one possible development route being a laboratory-developed test (LDT).